Editorial

Continuation of Oral Medications When Insulin Is Initiated

Authors: Joshua J. Neumiller, PharmD, CDE, CGP, FASCP, Stephen M. Setter, PharmD, CGP, CDE, FASCP

Abstract

Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by insulin resistance and progressive β-cell dysfunction.1 With the prevalence of T2DM increasing, particularly in younger populations, the use of insulin will become increasingly important as patients develop severe insulinopenia due to a progressive loss of pancreatic β-cell function. The decision to initiate insulin therapy in many patients with T2DM is not always clear, with considerations for any given patient being quite diverse, and often complex. The clinician's views, experiences, and comfort level with the initiation and management of insulin in patients with T2DM often dictates their “resistance” or “acceptance” of utilizing insulin at appropriate times during patient management.2 All too often “insulin resistance” is provider driven.2 Therefore, once the clinical decision is made to intensify therapy in patients with T2DM, oral therapies are often sought in lieu of insulin due to increased acceptance by patients (and by many providers) and less intense patient management and follow-up requirements, including the adjustment of concomitant oral antidiabetic agents. The article in this issue of SMJ titled “The Continuation of Oral Medications with the Initiation of Insulin Therapy in Type 2 Diabetes” provides a review and summary of the literature in regard to the efficacy, safety, and costs associated with the continuation of oral antidiabetic agents in combination with insulin.3 The authors point to the lack of guidance regarding the continuation or discontinuation of oral medications following insulin initiation and have thus undertaken the arduous task of summarizing currently available clinical trial data involving insulin use in conjunction with each major class of oral antidiabetic agents used in the management of T2DM.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc 2003;78:459–467.
 
2. Peyrot M, Ubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673–2679.
 
3. McFarland MS, Knight TN, Brown A, et al. The continuation of oral medications with the initiation of insulin therapy in type 2 diabetes: a review of the evidence. South Med J 2010;103:58–65.
 
4. Nathan DM, Buse BJ, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203.
 
5. Riddle MC. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favour. Diabetes Care 2008;31:S125–S130.
 
6. ACE/AACE Diabetes Road Map Task Force, 2008. Road Maps to Achieve Glycemic Control in Type 2 diabetes. Available at: http://www.metcare.com/files/roadmap-to-achieve-glycemic-control.pdf. Accessed July 22, 2009.
 
7. AACE/ACE. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(suppl 1):3–68.
 
8. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005;23:78–86.